X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall

MT Newswires Live

2025/02/06

X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.

The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.

X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.

The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.

Shares of X4 fell 6% in recent trading.

Price: 0.58, Change: -0.04, Percent Change: -6.00

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2509082212"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509082212\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509082212?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 23:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509082212","market":"sh","top_or_hot":-1,"title":"X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.</p><p>The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.</p><p>X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.</p><p>The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.</p><p>Shares of X4 fell 6% in recent trading.</p><p>Price: 0.58, Change: -0.04, Percent Change: -6.00</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>X4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nX4 Pharmaceuticals to Cut 30% of Workforce, Close Austria Facility; Shares Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-06 23:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.</p><p>The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.</p><p>X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.</p><p>The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.</p><p>Shares of X4 fell 6% in recent trading.</p><p>Price: 0.58, Change: -0.04, Percent Change: -6.00</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XFOR","symbol_name":"X4制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2509082212","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509082212","pubTimestamp":1738856227,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.The compa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XFOR":"X4制药","BK4139":"生物科技"},"translate_title":"X4 Pharmaceuticals裁员30%，关闭奥地利工厂；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XFOR":0.9},"content_text":"X4 Pharmaceuticals (XFOR) said Thursday that it is reducing its headcount by 43 employees, or about 30% of the workforce, ending research activities, and closing the Vienna, Austria facility.The company said it expects to save $30 million to $35 million annually and have enough funds to support operations through H1 2026. The workforce reductions will be completed by Q1 2025.X4 said it is restructuring its workforce and capital spending to focus on advancing mavorixafor for chronic neutropenia and promoting Xolremdi, or mavorixafor, in the US for warts, hypogammaglobulinemia, infections and myelokathexis syndrome.The company is also pausing pre-clinical drug programs and scaling down the US commercial field team.Shares of X4 fell 6% in recent trading.Price: 0.58, Change: -0.04, Percent Change: -6.00","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}